title: The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
authors.affiliation: University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah.
authors.forename: Robert H
authors.initials: RH
authors.lastname: Andtbacka
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D008545:Melanoma / Q000235:genetics / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D050130:Oncolytic Virotherapy / Q000009:adverse effects / Q000379:methods*; D050504:Oncolytic Viruses / Q000145:classification / Q000235:genetics; D019076:Transgenes; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents